960 x 350_41

Discovery Bioanalysis

Identifying candidates with promising ADME and pharmacokinetics properties during the discovery phase of drug development lays the groundwork for future clinical trials and regulatory approval. However, translating a long-term study into a successful outcome requires reliable, qualified measurements at a clinical scale.


Q2 Solutions’ global bioanalytical services network brings substantial expertise in biomarker assays and cell-based bioanalytical assays that target multi-domain proteins, antibodies, oligonucleotides, antibody-drug conjugates, and peptides.


Specific strengths include:

  • ADME assay development (including drug-drug interaction testing, discovery and development metabolite identification, and in vitro ADME screening)
  • Ligand-binding assays
  • Pharmacokinetic (PK) testing
  • Immunogenicity testing and immunoassays
  • Biomarker assays
  • Large molecule bioanalysis and LC/MS bioanalysis
  • DMPK services

Q² Solutions can work with you to develop automated small molecule LC/MS assays, large molecule ligand binding assays, immunoassays, and large-molecule hybrid-LC/MS assays to meet your discovery bioanalysis needs.

Q² Solutions can help you design and carry out validated assays that will move your project forward

Component 89 – 49

Assay Development for Large-Scale Clinical Studies

Supporting data from high-volume, regulated clinical studies

Component 89 – 50

Large Molecule Bioanalytical and ADME Solutions

Solutions for your large molecule bioanalysis and the successful outcome you seek

Related Thought Leaders Insights

Hybrid Assays for Protein Bioanalysis

Authors: Steve Lowes, Ph.D., Senior Director, Bioanalytical Services Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers Hybrid assays are powerful tools for protein bioanalysis of both...

Quantitative Assays for Peptides using LC-MS

We are one of the few bioanalytical laboratories successfully employing immunoprecipitation techniques, HRMS, and multi-dimensional liquid chromatography for the quantitation of peptide and protein...

Developing Assays for Novel Drugs

Novel drugs with complex design are becoming more common to treat difficult diseases. This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones,...